Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Сердечная недостаточность, сахарный диабет и риск гипогликемий: требуйте невозможного!
Сердечная недостаточность, сахарный диабет и риск гипогликемий: требуйте невозможного!
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Clark CM, Perry RC. Type 2 diabetes and macro vascular disease. Epidemiology and etiology. Am Heart J 1999.
2. The CONSENSUS trial study group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–35.
3. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293–302.
4. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10.
5. Packer M, Poole-Wilson PA, Armstrong PM et al. on behalf of the ATLAS Study Group. Comparative effects of low doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure. Submitted, 1998.
6. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19: 481–9.
7. Suskin N, McKelvie RS, Roteaus J. Increased insulin and glucose levels in heart failure. J Am Coll Cardiol 1998; 3 (Suppl.): 249A.
8. Schindler DM, Kostis JB, Yusuf S et al. For the SOLVD investigators. Diabetes mellitus: a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996; 77: 1017–20.
9. Chae CU, Glynn RJ, Manson JE et al. Diabetes predicts congestive heart failure risk in the elderly. Circulation 1998; 98 (Suppl. I): 721.
10. Detry JM. The pathophysiology of myocardial ischaemia. Eur Heart J 1996; 17 (Suppl. G): 48–52.
11. Youkoyama I, Momomura SI, Ohtake T et al. Reduced myocardial flow reserve in non–insulin–dependent diabetes mellitus. J Am Coll Cardiol 1997; 30: 1472–7.
12. Lundbæck K. Diabetic angiopathy: a specific vascular disease. Lancet 1954; 2: 377–9.
13. Ewing D. Cardiac autonomic neuropathy. In: Jarret R ed. Diabetes and heart disease. Amsterdam: Elsevier 1984: 99–132.
14. Amato L, Paolisso G, Cacciatore F et al. on behalf of the observatorio geriatrico regione campania group. Congastive heart failure predicts the development of non-insulin dependent diabetes mellitus in the elderly. Diabetes Metab 1997; 23: 213–8.
15. Mosterd A, Cost B, Hoes AW et al. The prognosis of heart failure in the general population. The Rotterdam Study. Eur Heart J 2001; 22: 1318–27.
16. De Groote P, Lamblin N, Mouquet F et al. Impact of diabetes mellitus on long-term survival in patients with congastive heart failure. Eur Heart J 2004; 25: 656–62.
17. Thrainsdottir IS, Aspelund T, Hardarson T et al. Glucose abnormalities and heart failure prognosis in the population based Reykjavik Study. Eur J Cardiovasc Prev Rehabil 2005; 12: 465–71.
18. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: full text. Eur Heart J 2007; 1–72.
19. Haas SJ, Vos T, Gilbert RE, Krum H. Are β-Blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146: 848–53.
20. Hjalmarson A, Goldstein S, Fagerberg B et al. For the MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283: 1295–302.
21. Deedwania PC, Giles TD, Klibaner M et al. MERIT-HF Study Group. Efficacy, safety nd tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005; 149: 159–67.
22. Packer M, Coats AJ, Fowler MB et al for the Carvedilol Prospective Randomized Cumulative Survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651–8.
23. Pool-Wilson PA, Swedberg K, Cleland JG et al. for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003; 57: 601–9.
24. McGill JB, Bakris GL, Fonseca V et al. b-Blocker use and diabetes symptom score: results from the GEMINI study. Diabetes, Obesity and Metabolism 2007; 9: 408–17.
25. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in pationts with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227–36.
26. Мордовин В.Ф., Белокопытова Н.В., Фальковская А.Ю., Ефимова И.Ю. Гипотензивная эффективность и церебропротективные свойства карведилола у больных артериальной гипертонией, ассоциированной с сахарным диабетом 2 типа. Кардиология, 2007; 10: 31–6.
27. Аметов А.С., Гиляревския С.Р., Дикова Т.Е., Сокарева Е.В. Коррекция ранних нарушений функции сердца у больных сахарным диабетом 2 типа. Сердце, 2008; 1: 61–3.
28. Лукина Ю.В., Марцевич С.Ю., Деев А.Д., Шальнова С.А. Cравнительное контролируемое исследование антигипертензивной эффективности и безопасности терапии карведилолом у больных артериальной гипертонией и ожирением или сахарным диабетом 2-го типа (по результатам многоцентрового исследования АККОРД) Рациональная фармакотерапия в кардиологии, 2009; 3: 19–24.
29. Гиляревский С.Р., Столярова Н.И., Новикова Ю.П. и др. Эффективность и безопасность применения карведилола и бисопролола при лечении хронической сердечной недостаточности у больных сахарным диабетом 2 типа. Сердечная недостаточность, 2004; 4: 137–9.
30. Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Тарыкина Е.В. Блокаторы b-адренорецепторов в лечении сердечно-сосудистых заболеваний: место карведилола. Кардиология, 2006; 12.
31. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. b-Blockers and sudden cardiac death. Annals of Internal Medicine 1995; 123: 358–67.
32. Skinner JE, Reguation of cardiac vulnerability by the cerebral defence system. JACC 1985; 5: 88B–94B.
33. Townend JN, Litter WA. Cardiac vagal activity: a target for intervention in heart disease. Lancet 1995; 345: 937–8.
34. Delsperger KC, Martins JB, Clothier JL, Marcus ML. Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic beta blockade. Circulation 1990; 82: 941–50.
35. Parker GW, Michael LH, Hartley CJ, Skinner JE et al. Central beta-adrenergic mechanisms may modulate ischemicventricular fibrillation in pigs. Circulation Research 1990; 66: 259–70.
36. Ablad B, Bjuro T, Bjorkman JA et al. Role of central nervous beta-adrenoreceptors in the prevention of ventricular fibrillation through the augmentation of cardiac vagal tone. JACC 1991; 17: 165A.
37. Hoffman R, Sinkey C, Dopp J, Phillips B. Systemic and Local Adrenergic Regulation of Muscle Glucose Utiliztaion during Hypoglycemia in healthy subjects. Diabetes 2002; 51: 734–42.
38. Flechtner M, Jenkinson C, Alt A. et al. Sympathetic regulation of glucose uptake by the a1-Adrenoreceptor in human obesity. Obesity Research 2004; 12 (4): 612–20.
39. Moy J, Batest J, Fisher R. Effects of Nutric Oxide on platelet-activating Factor and a-adrenergic-stimulated vasoconstriction and glycogenolysis in the perfused rat liver. J Biol Chem 1991; 13 (266): 8092–6.
40. Chang An Chu, Sindeler DR, Kayano Igawa et al. The direct effects of catecholamines on hepatic glucose production occur via a1- and βb2-receptors in the dog. Am J Physiol Endocrinol Metab 2000; 279: E463–E473.
2. The CONSENSUS trial study group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–35.
3. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293–302.
4. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10.
5. Packer M, Poole-Wilson PA, Armstrong PM et al. on behalf of the ATLAS Study Group. Comparative effects of low doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure. Submitted, 1998.
6. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19: 481–9.
7. Suskin N, McKelvie RS, Roteaus J. Increased insulin and glucose levels in heart failure. J Am Coll Cardiol 1998; 3 (Suppl.): 249A.
8. Schindler DM, Kostis JB, Yusuf S et al. For the SOLVD investigators. Diabetes mellitus: a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996; 77: 1017–20.
9. Chae CU, Glynn RJ, Manson JE et al. Diabetes predicts congestive heart failure risk in the elderly. Circulation 1998; 98 (Suppl. I): 721.
10. Detry JM. The pathophysiology of myocardial ischaemia. Eur Heart J 1996; 17 (Suppl. G): 48–52.
11. Youkoyama I, Momomura SI, Ohtake T et al. Reduced myocardial flow reserve in non–insulin–dependent diabetes mellitus. J Am Coll Cardiol 1997; 30: 1472–7.
12. Lundbæck K. Diabetic angiopathy: a specific vascular disease. Lancet 1954; 2: 377–9.
13. Ewing D. Cardiac autonomic neuropathy. In: Jarret R ed. Diabetes and heart disease. Amsterdam: Elsevier 1984: 99–132.
14. Amato L, Paolisso G, Cacciatore F et al. on behalf of the observatorio geriatrico regione campania group. Congastive heart failure predicts the development of non-insulin dependent diabetes mellitus in the elderly. Diabetes Metab 1997; 23: 213–8.
15. Mosterd A, Cost B, Hoes AW et al. The prognosis of heart failure in the general population. The Rotterdam Study. Eur Heart J 2001; 22: 1318–27.
16. De Groote P, Lamblin N, Mouquet F et al. Impact of diabetes mellitus on long-term survival in patients with congastive heart failure. Eur Heart J 2004; 25: 656–62.
17. Thrainsdottir IS, Aspelund T, Hardarson T et al. Glucose abnormalities and heart failure prognosis in the population based Reykjavik Study. Eur J Cardiovasc Prev Rehabil 2005; 12: 465–71.
18. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: full text. Eur Heart J 2007; 1–72.
19. Haas SJ, Vos T, Gilbert RE, Krum H. Are β-Blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146: 848–53.
20. Hjalmarson A, Goldstein S, Fagerberg B et al. For the MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283: 1295–302.
21. Deedwania PC, Giles TD, Klibaner M et al. MERIT-HF Study Group. Efficacy, safety nd tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005; 149: 159–67.
22. Packer M, Coats AJ, Fowler MB et al for the Carvedilol Prospective Randomized Cumulative Survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651–8.
23. Pool-Wilson PA, Swedberg K, Cleland JG et al. for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003; 57: 601–9.
24. McGill JB, Bakris GL, Fonseca V et al. b-Blocker use and diabetes symptom score: results from the GEMINI study. Diabetes, Obesity and Metabolism 2007; 9: 408–17.
25. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in pationts with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227–36.
26. Мордовин В.Ф., Белокопытова Н.В., Фальковская А.Ю., Ефимова И.Ю. Гипотензивная эффективность и церебропротективные свойства карведилола у больных артериальной гипертонией, ассоциированной с сахарным диабетом 2 типа. Кардиология, 2007; 10: 31–6.
27. Аметов А.С., Гиляревския С.Р., Дикова Т.Е., Сокарева Е.В. Коррекция ранних нарушений функции сердца у больных сахарным диабетом 2 типа. Сердце, 2008; 1: 61–3.
28. Лукина Ю.В., Марцевич С.Ю., Деев А.Д., Шальнова С.А. Cравнительное контролируемое исследование антигипертензивной эффективности и безопасности терапии карведилолом у больных артериальной гипертонией и ожирением или сахарным диабетом 2-го типа (по результатам многоцентрового исследования АККОРД) Рациональная фармакотерапия в кардиологии, 2009; 3: 19–24.
29. Гиляревский С.Р., Столярова Н.И., Новикова Ю.П. и др. Эффективность и безопасность применения карведилола и бисопролола при лечении хронической сердечной недостаточности у больных сахарным диабетом 2 типа. Сердечная недостаточность, 2004; 4: 137–9.
30. Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Тарыкина Е.В. Блокаторы b-адренорецепторов в лечении сердечно-сосудистых заболеваний: место карведилола. Кардиология, 2006; 12.
31. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. b-Blockers and sudden cardiac death. Annals of Internal Medicine 1995; 123: 358–67.
32. Skinner JE, Reguation of cardiac vulnerability by the cerebral defence system. JACC 1985; 5: 88B–94B.
33. Townend JN, Litter WA. Cardiac vagal activity: a target for intervention in heart disease. Lancet 1995; 345: 937–8.
34. Delsperger KC, Martins JB, Clothier JL, Marcus ML. Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic beta blockade. Circulation 1990; 82: 941–50.
35. Parker GW, Michael LH, Hartley CJ, Skinner JE et al. Central beta-adrenergic mechanisms may modulate ischemicventricular fibrillation in pigs. Circulation Research 1990; 66: 259–70.
36. Ablad B, Bjuro T, Bjorkman JA et al. Role of central nervous beta-adrenoreceptors in the prevention of ventricular fibrillation through the augmentation of cardiac vagal tone. JACC 1991; 17: 165A.
37. Hoffman R, Sinkey C, Dopp J, Phillips B. Systemic and Local Adrenergic Regulation of Muscle Glucose Utiliztaion during Hypoglycemia in healthy subjects. Diabetes 2002; 51: 734–42.
38. Flechtner M, Jenkinson C, Alt A. et al. Sympathetic regulation of glucose uptake by the a1-Adrenoreceptor in human obesity. Obesity Research 2004; 12 (4): 612–20.
39. Moy J, Batest J, Fisher R. Effects of Nutric Oxide on platelet-activating Factor and a-adrenergic-stimulated vasoconstriction and glycogenolysis in the perfused rat liver. J Biol Chem 1991; 13 (266): 8092–6.
40. Chang An Chu, Sindeler DR, Kayano Igawa et al. The direct effects of catecholamines on hepatic glucose production occur via a1- and βb2-receptors in the dog. Am J Physiol Endocrinol Metab 2000; 279: E463–E473.
Авторы
А.А.Александров1, О.А.Шацкая1, С.С.Кухаренко1, Е.Н.Дроздова1, М.Н.Ядрихинская1, И.И.Чукаева2
ФГБУ Эндокринологический научный центр Минздравсоцразвития РФ;
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздравсоцразвития РФ
ФГБУ Эндокринологический научный центр Минздравсоцразвития РФ;
ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздравсоцразвития РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.